• Announcements

    • Joelf

      Upgraded Sclero Forums!   05/18/2017

      Welcome to the Upgraded and Redesigned Sclero Forums!!   Our Forums are even better and more up to date than before.   Happy Posting to all our Members!!
Sign in to follow this  
Followers 0
Joelf

Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic (CADM) and myopathic dermatomyositis (DM).

1 post in this topic

Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic (CADM) and myopathic dermatomyositis (DM).

 

Anti-MDA5 antibody is significantly associated with interstitial lung disease, rapidly progressing interstitial lung disease, worse pulmonary outcome, and survival in US classic DM and CADM patients. PubMed, Arthritis Care Res (Hoboken), 09/28/2015. (Also see Myopathy and Myositis)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

ISN Chat Host

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now
Sign in to follow this  
Followers 0